MARKETING AUTHORISATION

Arthur Cummings
Published: Monday, April 13, 2015
Santen Pharmaceutical has announced that the European Medicines Agency (EMA) has accepted the company’s Marketing Authorisation Application (MAA) filing for the use of intravitreal sirolimus, an investigational mTOR inhibitor, for the treatment of noninfectious uveitis (NIU) of the posterior segment.
“Given the risks associated with currently available therapeutic options for NIU of the posterior segment, a chronic inflammatory condition in many cases, there is a significant need for novel treatments that could be used,” says Dr Naveed Shams, Chief Scientific Officer and Head, Global R&D, Santen Ltd.
www.santeninc.com
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.